Professor Andrew Tobin

Professor of Molecular Pharmacology (Molecular Biosciences)
Director of the Advanced Research Centre (Research & Innovation Services)

Biography

Andrew attended Queen Mary College, University of London where he attained a 1st class honours degree in Biochemistry. Following D.Phil studies at the University of Oxford under the supervision of Dr. Neville Osborne at the Nuffield Laboratory of Ophthalmology Andrew spent two years at Bristol Myers, Squibb in Princeton, New Jersey working with Mariano Barbacid on oncogene discovery. Returning to the UK in 1991 as a post doctoral fellow at the University of Leicester with Stefan Nahorski allowed Andrew to research mechanisms of regulation of G protein coupled receptors (GPCRs). He establish an independent group in 1996 with the first of three Wellcome Trust Senior Research Fellowships (SRF). Primarily focused on the physiological function and modes of drug action at GPCRs, Andrew’s group have investigated key novel paradigms in GPCR biology. In particular, he has generated novel genetic and chemical genetic mouse models as well as employed mouse models of disease to define the action of GPCR targeted drugs in the regulation and modification of human diseases including neurodegeneration.

During this time Andrew became interested in employing the pharmacological principles and the technologies developed in the GPCR work to the question of probing essential pathways in the malaria parasite with the aim of developing novel therapeutics. In this work he has focused on protein phosphorylation and described for the first time the essential protein kinases in the human malarial parasite P. falciparum. His group were among the first to publish the global phospho-proteome of the malarial parasite. He is now developing novel protein kinases inhibitors that selectively target essential parasite kinases with the aim of generating next generation anti-malarial’s.

Now at the University of Glasgow Andrew has established the Centre for Translational Pharmacology aimed at drawing together his interests in GPCRs and protein kinases into a Centre focused on defining the novel paradigms in pharmacology that will allow for the rational design of next generation drugs.

Research interests

The Tobin laboratory has two primary areas of research. The first is our long-standing interest in G protein coupled receptor (GPCR) research which has spanned more than two decades. Primarily, focused on understanding how mechanisms of receptor post-translational modification regulate GPCR signalling in vitro and in vivo the group have used novel genetic mouse strains, mouse disease models and novel pharmacological entities to probe the function and therapeutic potential of targeting an array of GPCRs.

The second area of focus of the Tobin laboratory has been our relatively recent application of proteomic, cell biological, chemical genetic and pharmacological approaches to defining the essential phospho-signalling cascades in malaria and how to target these in the development of next generation anti-malarials.

Layman’s summary:
“We have for many years been studying the way drugs work and how we might design better drugs to treat human disease in the future. We have focused much of our work on a group of proteins that are present on the surface of cells and that respond to chemical messengers that are released by one cell and that activate another cell. These proteins are called receptors and although many drugs currently on the market, such as anti-histamines for allergies and beta-blockers for heart disease, target these receptor proteins, largely drug discovery efforts in this area fail. We are using an array of new technologies that include genetically engineered mice, to work out why these drug discovery projects fail and how we might overcome these failures in the future to make better drugs.

In concert with these studies is our work to inhibit processes in the human malarial parasite that are essential for the survival of the parasite. In these studies, we are specifically investigating the role of a universal biochemical process called protein phosphorylation that we have discovered is essential for parasite survival. By developing inhibitors that will stop protein phosphorylation in the parasite we hope to make the next generation of anti-malarials.”

Team Tobin Impact in 60 seconds video

Research interests - further information
Centre for Translational Pharmacology
Molecular Pharmacology

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011

Number of items: 82.

2023

Barki, N. et al. (2023) Phosphorylation bar-coding of free fatty acid receptor 2 is generated in a tissue-specific manner. eLife, 12, RP91861. (doi: 10.7554/eLife.91861) (PMID:38085667) (PMCID:PMC10715726)

Ganguly, A. et al. (2023) G protein-receptor kinases 5/6 are the key regulators of G protein-coupled receptor 35-arrestin interactions. Journal of Biological Chemistry, 299(10), 105218. (doi: 10.1016/j.jbc.2023.105218) (PMID:37660910) (PMCID:PMC10520886)

Vuckovic, Z. et al. (2023) Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics. eLife, 12, e83477. (doi: 10.7554/elife.83477) (PMID:37248726) (PMCID:PMC10229135)

Dean, B., Bakker, G., Ueda, H. R., Tobin, A. B. , Brown, A. and Kanaan, R. A. A. (2023) A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Frontiers in Cellular Neuroscience, 17, 1124333. (doi: 10.3389/fncel.2023.1124333) (PMID:36909280) (PMCID:PMC9992992)

Ong, H. W., Adderley, J., Tobin, A. B. , Drewry, D. H. and Doerig, C. (2023) Parasite and host kinases as targets for antimalarials. Expert Opinion on Therapeutic Targets, 27(2), pp. 151-169. (doi: 10.1080/14728222.2023.2185511) (PMID:36942408)

Nguyen, H. T. M., van der Westhuizen, E. T., Langmead, C. J., Tobin, A. B. , Sexton, P. M., Christopoulos, A. and Valant, C. (2023) Opportunities and challenges for the development of M1 muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits. British Journal of Pharmacology, (doi: 10.1111/bph.15982) (PMID:36355830) (Early Online Publication)

2022

Dwomoh, L. et al. (2022) M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease. Science Signaling, 15(760), eabm3720. (doi: 10.1126/scisignal.abm3720) (PMID:36378750)

Alharbi, A. G., Tobin, A. B. and Milligan, G. (2022) How arrestins and GRKs regulate the function of long chain fatty acid receptors. International Journal of Molecular Sciences, 23(20), 12237. (doi: 10.3390/ijms232012237) (PMID:36293091) (PMCID:PMC9602559)

Marsango, S., Barki, N., Jenkins, L. , Tobin, A. B. and Milligan, G. (2022) Therapeutic validation of an orphan G protein-coupled receptor: the case of GPR84. British Journal of Pharmacology, 179(14), pp. 3529-3541. (doi: 10.1111/bph.15248) (PMID:32869860) (PMCID:PMC9361006)

Marsango, S. et al. (2022) The M1 muscarinic receptor is present in situ as a ligand-regulated mixture of monomers and oligomeric complexes. Proceedings of the National Academy of Sciences of the United States of America, 119(24), e220110311. (doi: 10.1073/pnas.2201103119) (PMID:35671422) (PMCID:PMC9214538)

Marsango, S. et al. (2022) Selective phosphorylation of threonine residues defines GPR84-arrestin interactions of biased ligands. Journal of Biological Chemistry, 298(5), 101932. (doi: 10.1016/j.jbc.2022.101932) (PMID:35427647) (PMCID:PMC9118924)

Dwomoh, L. , Tejeda, G. S. and Tobin, A. B. (2022) Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal Signaling, 6(1), NS20210004. (doi: 10.1042/NS20210004) (PMID:35571495) (PMCID:PMC9069568)

Barki, N. et al. (2022) Chemogenetics defines the roles of short chain fatty acid receptors within the gut-brain axis. eLife, 11, e73777. (doi: 10.7554/eLife.73777) (PMID:35229717) (PMCID:PMC8887895)

Divorty, N., Jenkins, L. , Ganguly, A., Butcher, A. J., Hudson, B. D. , Schulz, S., Tobin, A. B. , Nicklin, S. A. and Milligan, G. (2022) Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. Journal of Biological Chemistry, 298(3), 101655. (doi: 10.1016/j.jbc.2022.101655) (PMID:35101446) (PMCID:PMC8892012)

2021

Scarpa, M. et al. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 118(50), e2107389118. (doi: 10.1073/pnas.2107389118) (PMID:34893539) (PMCID:PMC8685681)

Lin, L.-C., Quon, T., Engberg, S., Mackenzie, A. E., Tobin, A. B. and Milligan, G. (2021) G protein-coupled receptor GPR35 suppresses lipid accumulation in hepatocytes. ACS Pharmacology and Translational Science, 4(6), pp. 1835-1848. (doi: 10.1021/acsptsci.1c00224) (PMID:34927014)

Brown, A. J.H. et al. (2021) From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease. Cell, 184(24), 5886-5901.e22. (doi: 10.1016/j.cell.2021.11.001) (PMID:34822784)

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Milligan, G. et al. (2021) Discovery and characterization of novel antagonists of the proinflammatory orphan receptor GPR84. ACS Pharmacology and Translational Science, 4(5), pp. 1598-1613. (doi: 10.1021/acsptsci.1c00151) (PMID:34661077) (PMCID:PMC8506611)

Burger, W. A. C. et al. (2021) Identification of a novel allosteric site at the M5 muscarinic acetylcholine receptor. ACS Chemical Neuroscience, 12(16), pp. 3112-3123. (doi: 10.1021/acschemneuro.1c00383) (PMID:34351123)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

Bourgognon, J.-M. , Spiers, J. G., Robinson, S. W., Scheiblich, H., Glynn, P., Ortori, C., Bradley, S. J. , Tobin, A. B. and Steinert, J. R. (2021) Inhibition of neuroinflammatory nitric oxide signaling suppresses glycation and prevents neuronal dysfunction in mouse prion disease. Proceedings of the National Academy of Sciences of the United States of America, 118(10), e200957911. (doi: 10.1073/pnas.2009579118) (PMID:33653950)

Milligan, G. , Barki, N. and Tobin, A. (2021) Chemogenetic approaches to explore the functions of Free Fatty Acid Receptor 2. Trends in Pharmacological Sciences, 42(3), pp. 191-202. (doi: 10.1016/j.tips.2020.12.003) (PMID:33495026)

Mok, S. et al. (2021) Artemisinin-resistant K13 mutations rewire Plasmodium falciparum's intra-erythrocytic metabolic program to enhance survival. Nature Communications, 12, 530. (doi: 10.1038/s41467-020-20805-w) (PMID:33483501) (PMCID:PMC7822823)

Scammells, P. J. et al. (2021) Development of novel 4‐arylpyridin‐2‐one and 6‐arylpyrimidin‐4‐one positive allosteric modulators of the M1 muscarinic acetylcholine receptor. ChemMedChem, 16(1), pp. 216-233. (doi: 10.1002/cmdc.202000540) (PMID:32851779)

2020

Marti-Solano, M. et al. (2020) Combinatorial expression of GPCR isoforms affects signalling and drug responses. Nature, 587, pp. 650-656. (doi: 10.1038/s41586-020-2888-2) (PMID:33149304)

Mahindra, A., Janha, O., Mapesa, K., Sanchez Azqueta, A., Alam, M. M. , Amambua-Ngwa, A., Nwakanma, D. C., Tobin, A. B. and Jamieson, A. G. (2020) Development of potent PfCLK3 inhibitors based on TCMDC-135051 as a new class of antimalarials. Journal of Medicinal Chemistry, 63(17), pp. 9300-9315. (doi: 10.1021/acs.jmedchem.0c00451) (PMID:32787140) (PMCID:PMC7497403)

Prihandoko, R. et al. (2020) Pathophysiological regulation of lung function by the free fatty acid receptor FFA4. Science Translational Medicine, 12(557), eaaw9009. (doi: 10.1126/scitranslmed.aaw9009) (PMID:32817367)

Quon, T., Lin, L.-C., Ganguly, A., Tobin, A. B. and Milligan, G. (2020) Therapeutic opportunities and challenges in targeting the orphan G protein-coupled receptor GPR35. ACS Pharmacology and Translational Science, 3(5), pp. 801-812. (doi: 10.1021/acsptsci.0c00079) (PMID:33073184)

Vanaerschot, M. et al. (2020) Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. Cell Chemical Biology, 27(7), 806-816.e8. (doi: 10.1016/j.chembiol.2020.04.001) (PMID:32359426) (PMCID:PMC7369637)

Thompson, K. J. and Tobin, A. B. (2020) Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease? Cellular Signalling, 70, 109545. (doi: 10.1016/j.cellsig.2020.109545) (PMID:31978506) (PMCID:PMC7184673)

Sommer, M. E. et al. (2020) The European Research Network on Signal Transduction (ERNEST): toward a multidimensional holistic understanding of G protein-coupled receptor signaling. ACS Pharmacology and Translational Science, 3(2), pp. 361-370. (doi: 10.1021/acsptsci.0c00024) (PMID:32296774) (PMCID:PMC7155379)

Tobin, A. B. and Bradley, S. J. (2020) Editorial for Advances in G Protein-Coupled Receptor Signal Transduction Special Issue. ACS Pharmacology and Translational Science, 3(2), pp. 169-170. (doi: 10.1021/acsptsci.0c00029) (PMID:32296759)

Verweij, E. W. E., Al Araaj, B., Prabhata, W. R., Prihandoko, R., Nijmeijer, S., Tobin, A. B. , Leurs, R. and Vischer, H. F. (2020) Differential role of serines and threonines in intracellular loop 3 and C-terminal tail of the histamine H4 receptor in β-arrestin and G protein-coupled receptor kinase interaction, internalization, and signaling. ACS Pharmacology and Translational Science, 3(2), pp. 321-333. (doi: 10.1021/acsptsci.0c00008) (PMID:32296771) (PMCID:PMC7155198)

Rexen Ulven, E. et al. (2020) Structure-activity relationship studies of tetrahydroquinolone free fatty acid receptor 3 modulators. Journal of Medicinal Chemistry, 63(7), pp. 3577-3595. (doi: 10.1021/acs.jmedchem.9b02036) (PMID:32141297) (PMCID:PMC7307922)

Bradley, S. J. et al. (2020) Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nature Chemical Biology, 16(3), pp. 240-249. (doi: 10.1038/s41589-019-0453-9) (PMID:32080630)

Khajehali, E., Bradley, S. , van der Westhuizen, E. T., Molloy, C. , Valant, C., Finlayson, L. , Lindsley, C. W., Sexton, P. M., Tobin, A. B. and Christopoulos, A. (2020) Restoring agonist function at a chemogenetically modified M₁ muscarinic acetylcholine receptor. ACS Chemical Neuroscience, 11(24), pp. 4270-4279. (doi: 10.1021/acschemneuro.0c00540) (PMID:33196174)

2019

Vuckovic, Z. et al. (2019) Crystal structure of the M5 muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 116(51), pp. 26001-26007. (doi: 10.1073/pnas.1914446116) (PMID:31772027) (PMCID:PMC6926013)

Alam, M. M. et al. (2019) Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682. (doi: 10.1126/science.aau1682) (PMID:31467193)

Thompson, K.J., Khajehali, E., Molloy, C. , Valant, C., Bradley, S.J. , Sexton, P.M., Christopoulos, A. and Tobin, A.B. (2019) The In Vitro Characterisation of DREADD Agonist 21, a Novel Ligand for Muscarinic DREADD Receptors. British Journal of Pharmacology 176(16): 3002-3003. Selected Abstract from Pharmacology 2018, London, UK, 18-20 Dec 2018. (doi: 10.1111/bph.14681)

Bolognini, D. et al. (2019) Chemogenetics defines receptor-mediated functions of short chain free fatty acids. Nature Chemical Biology, 15(5), pp. 489-498. (doi: 10.1038/s41589-019-0270-1) (PMID:30992568)

Mackenzie, A. E., Quon, T., Lin, L.-C., Hauser, A. S., Jenkins, L. , Inoue, A., Tobin, A. B. , Gloriam, D. E., Hudson, B. D. and Milligan, G. (2019) Receptor selectivity between the G proteins Gα12 and Gα13 is defined by a single leucine-to-isoleucine variation. FASEB Journal, 33(4), pp. 5005-5017. (doi: 10.1096/fj.201801956R) (PMID:30601679) (PMCID:PMC6436656)

Jörg, M. et al. (2019) 6-Phenylpyrimidin-4-ones as positive allosteric modulators at the M1 mAChR: the determinants of allosteric activity. ACS Chemical Neuroscience, 10(3), pp. 1099-1114. (doi: 10.1021/acschemneuro.8b00613) (PMID:30547573)

Mancini, S., Mahmud, Z. A., Jenkins, L. , Bolognini, D., Newman, R., Barnes, M., Edye, M. E., McMahon, S. B., Tobin, A. B. and Milligan, G. (2019) On-target and off-target effects of novel orthosteric and allosteric activators of GPR84. Scientific Reports, 9, 1861. (doi: 10.1038/s41598-019-38539-1) (PMID:30755705) (PMCID:PMC6372602)

Müskens, F. M., Ward, R. J., Herkt, D., van de Langemheen, H., Tobin, A. B. , Liskamp, R. M.J. and Milligan, G. (2019) Design, synthesis and evaluation of a diazirine photoaffinity probe for ligand-based receptor capture targeting G protein-coupled receptors. Molecular Pharmacology, 95(2), pp. 196-209. (doi: 10.1124/mol.118.114249) (PMID:30514721) (PMCID:PMC6324650)

2018

Thompson, K. J. et al. (2018) DREADD agonist 21 is an effective agonist for muscarinic-based DREADDs in vitro and in vivo. ACS Pharmacology and Translational Science, 1(1), pp. 61-72. (doi: 10.1021/acsptsci.8b00012) (PMID:30868140) (PMCID:PMC6407913)

Bourgognon, J.-M. , Spiers, J. G., Scheiblich, H., Antonov, A., Bradley, S. J. , Tobin, A. B. and Steinert, J. R. (2018) Alterations in neuronal metabolism contribute to the pathogenesis of prion disease. Cell Death and Differentiation, 25(8), pp. 1408-1425. (doi: 10.1038/s41418-018-0148-x) (PMID:29915278) (PMCID:PMC6113283)

Khajehali, E., Valant, C., Jörg, M., Tobin, A. B. , Conn, P. J., Lindsley, C. W., Sexton, P. M., Scammells, P. J. and Christopoulos, A. (2018) Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor. Biochemical Pharmacology, 154, pp. 243-254. (doi: 10.1016/j.bcp.2018.05.009) (PMID:29777683) (PMCID:PMC6066355)

Bradley, S. J. , Tobin, A. B. and Prihandoko, R. (2018) Muscarinic acetylcholine receptors in the central nervous system. Neuropharmacology, 136(Part C), p. 361. (doi: 10.1016/j.neuropharm.2018.06.012) (PMID:29894772)

van der Westhuizen, E. T. et al. (2018) Assessment of the molecular mechanisms of action of novel 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one allosteric modulators at the M1 muscarinic acetylcholine receptors. Molecular Pharmacology, 94(1), pp. 770-783. (doi: 10.1124/mol.118.111633) (PMID:29691279)

Bradley, S. J. , Tobin, A. B. and Prihandoko, R. (2018) The use of chemogenetic approaches to study the physiological roles of muscarinic acetylcholine receptors in the central nervous system. Neuropharmacology, 136(Part C), pp. 421-426. (doi: 10.1016/j.neuropharm.2017.11.043) (PMID:29191752)

Bradley, S. J. et al. (2018) Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes. Molecular Pharmacology, 93(6), pp. 645-656. (doi: 10.1124/mol.118.111872) (PMID:29695609) (PMCID:PMC5963591)

2017

Milligan, G. , Alvarez-Curto, E. , Hudson, B. D. , Prihandoko, R. and Tobin, A. B. (2017) FFA4/GPR120: pharmacology and therapeutic opportunities. Trends in Pharmacological Sciences, 38(9), pp. 809-821. (doi: 10.1016/j.tips.2017.06.006) (PMID:28734639) (PMCID:PMC5582618)

Bradley, S. J. et al. (2017) M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. Journal of Clinical Investigation, 127(2), pp. 487-499. (doi: 10.1172/JCI87526) (PMID:27991860) (PMCID:PMC5272187)

2016

Alvarez-Curto, E. , Inoue, A., Jenkins, L. , Raihan, S. Z., Prihandoko, R., Tobin, A. B. and Milligan, G. (2016) Targeted elimination of G proteins and arrestins defines their specific contributions to both intensity and duration of G protein-coupled receptor signalling. Journal of Biological Chemistry, 291(53), pp. 27147-27159. (doi: 10.1074/jbc.M116.754887) (PMID:27852822) (PMCID:PMC5207144)

Mitcheson, D. F. et al. (2016) A new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinase. Malaria Journal, 15(1), 535. (doi: 10.1186/s12936-016-1580-3) (PMID:27821169) (PMCID:PMC510031)

Zindel, D., Engel, S., Bottrill, A. R., Pin, J.-P., Prézeau, L., Tobin, A. B. , Bünemann, M., Krasel, C. and Butcher, A. J. (2016) Identification of key phosphorylation sites in PTH1R that determine arrestin3 binding and fine-tune receptor signaling. Biochemical Journal, 473(22), pp. 4173-4192. (doi: 10.1042/bcj20160740) (PMID:27623777) (PMCID:PMC5103873)

Bolognini, D. et al. (2016) A novel allosteric activator of free fatty acid 2 receptor displays unique Gi-functional bias. Journal of Biological Chemistry, 291, pp. 18915-18931. (doi: 10.1074/jbc.M116.736157) (PMID:27385588) (PMCID:PMC5009265)

Butcher, A. J. et al. (2016) An antibody biosensor establishes the activation of the M1 muscarinic acetylcholine receptor during learning and memory. Journal of Biological Chemistry, 291(17), pp. 8862-8875. (doi: 10.1074/jbc.M115.681726) (PMID:26826123) (PMCID:PMC4861454)

Bradley, S. J. et al. (2016) Mapping physiological G protein-coupled receptor signaling pathways reveals a role for receptor phosphorylation in airway contraction. Proceedings of the National Academy of Sciences of the United States of America, 113(16), pp. 4524-4529. (doi: 10.1073/pnas.1521706113) (PMID:27071102) (PMCID:PMC4843461)

Nuber, S., Zabel, U., Lorenz, K., Nuber, A., Milligan, G. , Tobin, A. B. , Lohse, M. J. and Hoffmann, C. (2016) β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature, 531, pp. 661-664. (doi: 10.1038/nature17198) (PMID:27007855)

Bouzo-Lorenzo, M., Santo-Zas, I., Lodeiro, M., Nogueiras, R., Casanueva, F. F., Castro, M., Pazos, Y., Tobin, A. B. , Butcher, A. J. and Camiña, J. P. (2016) Distinct phosphorylation sites on the ghrelin receptor, GHSR1a, establish a code that determines the functions of ß-arrestins. Scientific Reports, 6, p. 22495. (doi: 10.1038/srep22495) (PMID:26935831) (PMCID:PMC4776146)

Bolognini, D., Tobin, A. B. , Milligan, G. and Moss, C. E. (2016) The pharmacology and function of receptors for short-chain fatty acids. Molecular Pharmacology, 89(3), pp. 388-398. (doi: 10.1124/mol.115.102301) (PMID:26719580)

Bradley, S. J. and Tobin, A. B. (2016) Design of next-generation G protein–coupled receptor drugs: linking novel pharmacology and in vivo animal models. Annual Review of Pharmacology and Toxicology, 56(1), pp. 535-559. (doi: 10.1146/annurev-pharmtox-011613-140012) (PMID:26738479)

Prihandoko, R., Alvarez-Curto, E. , Hudson, B. D. , Butcher, A. J., Ulven, T., Miller, A. M., Tobin, A. B. and Milligan, G. (2016) Distinct phosphorylation clusters determines the signalling outcome of the free fatty acid receptor FFA4/GPR120. Molecular Pharmacology, 89(5), pp. 505-520. (doi: 10.1124/mol.115.101949) (PMID:26873857)

2015

Rossi, M. et al. (2015) CK2 acts as a potent negative regulator of receptor-mediated insulin release in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 112(49), E6818-E6824. (doi: 10.1073/pnas.1519430112) (PMID:26598688) (PMCID:PMC4679045)

Schrage, R. et al. (2015) The experimental power of FR900359 to study Gq-regulated biological processes. Nature Communications, 6, p. 10156. (doi: 10.1038/ncomms10156) (PMID:26658454) (PMCID:PMC4682109)

Brochet, M., Tobin, A. B. , Billker, O. and Doerig, C. (2015) The kinomics of malaria. In: Kraatz, H.-B. and Martic, S. (eds.) Kinomics: Approaches and applications. Wiley-VCH: Weinheim, pp. 115-136. ISBN 9783527337651 (doi: 10.1002/9783527683031.ch5)

Mitcheson, D. F., Tobin, A. B. and Alam, M. M. (2015) Applying chemical genetic tools to the study of phospho-signalling pathways in malaria parasites. Biochimica et Biophysica Acta: Proteins and Proteomics, 1854(10), pp. 1650-1656. (doi: 10.1016/j.bbapap.2015.06.014) (PMID:26143498)

Alam, M. M. et al. (2015) Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion. Nature Communications, 6, 7285. (doi: 10.1038/ncomms8285) (PMID:26149123) (PMCID:PMC4507021)

Willars, G. B., Tobin, A. B. and Challiss, R.A. J. (2015) British Pharmacological Society, 5th Focused Meeting on Cell Signalling: Matters arising …. British Journal of Pharmacology, 172(13), pp. 3194-3195. (doi: 10.1111/bph.13171) (PMID:26095874) (PMCID:PMC4500359)

Prihandoko, R., Bradley, S. J. , Tobin, A. and Butcher, A. J. (2015) Determination of GPCR phosphorylation status: establishing a phosphorylation barcode. Current Protocols in Pharmacology, 69, 2.13.1-2.13.26. (doi: 10.1002/0471141755.ph0213s69) (PMID:26344213)

Doerig, C., Rayner, J. C., Scherf, A. and Tobin, A. B. (2015) Post-translational protein modifications in malaria parasites. Nature Reviews Microbiology, 13(3), pp. 160-172. (doi: 10.1038/nrmicro3402) (PMID:25659318)

Zindel, D., Butcher, A. J., Al-Sabah, S., Lanzerstorfer, P., Weghuber, J., Tobin, A. B. , Bunemann, M. and Krasel, C. (2015) Engineered hyperphosphorylation of the 2-adrenoceptor prolongs arrestin-3 binding and induces arrestin internalization. Molecular Pharmacology, 87(2), pp. 349-362. (doi: 10.1124/mol.114.095422) (PMID:25425623) (PMCID:PMC4293452)

2014

Kern, S. et al. (2014) Inhibition of the SR protein-phosphorylating CLK kinases of plasmodium falciparum impairs blood stage replication and malaria transmission. PLoS ONE, 9(9), e105732. (doi: 10.1371/journal.pone.0105732) (PMID:25188378) (PMCID:PMC415485)

Tobin, A. and Prihandoko, R. (2014) Reply to "Letter to the editor: 'Systems biology versus reductionism in cell physiology'". American Journal of Physiology: Cell Physiology, 307(3), C310-C310. (doi: 10.1152/ajpcell.00192.2014) (PMID:25088763) (PMCID:PMC4121582)

Prihandoko, R. and Tobin, A. B. (2014) Challenges of assigning protein kinases to in vivo phosphorylation events. Focus on "Use of LC-MS/MS and Bayes' theorem to identify protein kinases that phosphorylate aquaporin-2 at Ser256". American Journal of Physiology: Cell Physiology, 307(2), C121-C122. (doi: 10.1152/ajpcell.00136.2014) (PMID:24829494)

Butcher, A. J., Hudson, B. D. , Shimpukade, B., Alvarez-Curto, E. , Prihandoko, R., Ulven, T., Milligan, G. and Tobin, A. B. (2014) Concomitant action of structural elements and receptor phosphorylation determine arrestin-3 interaction with the free fatty acid receptor FFA4. Journal of Biological Chemistry, 289, pp. 18451-18465. (doi: 10.1074/jbc.M114.568816) (PMID:24817122) (PMCID:PMC4140278)

Bradley, S. J. , Riaz, S. A. and Tobin, A. (2014) Employing novel animal models in the design of clinically efficacious GPCR ligands. Current Opinion in Cell Biology, 27, pp. 117-125. (doi: 10.1016/j.ceb.2013.12.002) (PMID:24680437) (PMCID:PMC3989050)

Graciotti, M., Alam, M. , Solyakov, L., Schmid, R., Burley, G., Bottrill, A. R., Doerig, C., Cullis, P. and Tobin, A. B. (2014) Malaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulation. PLoS ONE, 9(3), e85391. (doi: 10.1371/journal.pone.0085391) (PMID:24658579) (PMCID:PMC3962329)

2012

Lasonder, E., Treeck, M., Alam, M. and Tobin, A. B. (2012) Insights into the Plasmodium falciparum schizont phospho-proteome. Microbes and Infection, 14(10), pp. 811-819. (doi: 10.1016/j.micinf.2012.04.008) (PMID:22569589)

2011

Solyakov, L. et al. (2011) Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum. Nature Communications, 2, 565. (doi: 10.1038/ncomms1558) (PMID:22127061)

This list was generated on Fri Apr 19 22:04:43 2024 BST.

Jump to: Articles | Book Sections | Conference or Workshop Item

Number of items: 82.

Articles

Marti-Solano, M. et al. (2020) Combinatorial expression of GPCR isoforms affects signalling and drug responses. Nature, 587, pp. 650-656. (doi: 10.1038/s41586-020-2888-2) (PMID:33149304)

Alam, M. M. et al. (2019) Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682. (doi: 10.1126/science.aau1682) (PMID:31467193)

Book Sections

Conference or Workshop Item

This list was generated on Fri Apr 19 22:04:43 2024 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

GPR35: mechanisms of action and is agonism a potential therapeutic strategy for non-alcoholic fatty liver diseases
Medical Research Council
2023 - 2025
Targeting the malaria protein kinase PfCLK3
Medical Research Council
2022 - 2022
Novel roles of the short chain fatty acid receptors FFA2 and FFA3
Biotechnology and Biological Sciences Research Council
2022 - 2025
Development of next generation anti-malarials targeting the essential parasite protein kinase PfCLK3
Medical Research Council
2020 - 2022
Investigating disease networks and the mechanism of disease-modifying ligands in neurodegeneration: A proteomics approach
Alzheimer`s Research UK
2020 - 2021
Defining novel targets in neurodegenerative disease
Medical Research Scotland
2019 - 2023
DEL Screening against PfCLK3
Bill and Melinda Gates Foundation
2019 - 2020
Inhibitory G protein S-acylation as a therapeutic target in heart failure
British Heart Foundation
2019 - 2022
Defining physiological and pathophysiological roles of the Free Fatty Acid Receptor 2 by analysis of novel transgenic mouse models
Biotechnology and Biological Sciences Research Council (BBSRC)
2018 - 2021
Defining the functional modes of action, and therapeutic potential of targeting, the free fatty acid receptor FFA4 in the lung
Medical Research Council
2018 - 2020
Defining signal selection from the free fatty acid receptor FFA4; implications for
Biotechnology and Biological Sciences Research Council
2017 - 2021
MICA Pharmacological, molecular and cellular mechanisms of muscarinic slowing (modification) of neurodegenerative disease.
Medical Research Council
2017 - 2021
Defining the functional role of the enigmatic G protein coupled receptor GPR35 - Leicester application - PART B
Biotechnology and Biological Sciences Research Council
2017 - 2021
Collaborative Network to Define the Molecular Determinants of G Protein Coupled Receptor Clinical Efficacy
Wellcome Trust
2017 - 2021
Using a Designer Receptor Exclusively Activated by Designer Drug to define the role of short chain fatty acids in metabolic disease and inflammation
Biotechnology and Biological Sciences Research Council
2016 - 2019
GPR120: a G protein-coupled receptor with the potential to regulate insulin secretion and inflammation
Biotechnology and Biological Sciences Research Council
2016 - 2018
G Protein Coupled Receptor Clinical Efficacy
Wellcome Trust
2016 - 2021
Establishing the Centre for Translational Pharmacology
The Royal Society
2016 - 2021

Supervision

Gibson, Katharine
Investigation of the spreading of disease causing misfolded protein in neurodegenerative disease
Yin, Ruijing
function and regulation of GPR84

Research datasets

Jump to: 2023 | 2021

Number of items: 2.

2023

Barki, N., Jenkins, L. , Marsango, S., Dedeo, D. , Bolognini, D., Dwomoh, L. , Nilsen, M., Stoffels, M., Nagel, F., Schulz, S., Tobin, A. and Milligan, G. (2023) Phosphorylation bar-coding of Free Fatty Acid receptor 2 is generated in a tissue-specific manner. [Data Collection]

2021

Scarpa, M., Molloy, C. , Jenkins, L. , Strellis, B., Budgett, R., Hesse, S., Dwomoh, L. , Marsango, S., Tejeda, G. , Rossi, M., Ahmed, Z., Milligan, G. , Hudson, B. , Tobin, A. , Bradley, S. and Heptares, S. (2021) Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. [Data Collection]

This list was generated on Fri Apr 19 22:04:45 2024 BST.

Photo of Professor Andrew Tobin wearing a shirt and navy jumper against an abstract background in his lab

We use cookies

Necessary cookies

Analytics cookies

Hotjar and Clarity

Professor Andrew Tobin

Biography

Research interests

Publications

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2012

2011

Articles

Book Sections

Conference or Workshop Item

Grants

Supervision

Research datasets

2023

2021